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2 Administrative information 
2.1 List of abbreviations 
Abbreviation Explanation 
AE Adverse Event  
CI Chief Investigator 
CONSORT Consolidated Standards of Reporting Trials 
CRF Case Report Form 
CTU Clinical Trials Unit 
DMC Data Monitoring Committee 
DVT Deep Vein Thrombosis 
FARO Fixed Angle Removable Orthotic 
GCP Good Clinical Practice 
ICH International Conference on Harmonisation 
ISRCTN International Standard Randomised Controlled Trial Number 
HEAP Health Economics Analysis Plan 
MHRA Medicines and Healthcare products Regulatory Agency 
MOXFQ The Manchester-Oxford Foot Questionnaire 
MRC Medical Research Council 
MREC Multicentre Research Ethics Committee 
OMAS Olerud and Molander Ankle Score 
PE Pulmonary Embolism 
PI Principal Investigator 
PROM Patient Reported Outcome Measure 
QoL Quality of Life 
RCT Randomised Controlled Trial 
R&D Research and Development 
SAE Serious Adverse Event  
SAR Serious Adverse Reaction 
SOP Standard Operating Procedure 
TSC Trial Steering Committee 
WCTU Warwick Clinical Trials Unit 
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2.2 SAP amendments 
 
SAP 
version no. 
Protocol 
version 
Section(s) 
changed 
Details of SAP changes 
Date of 
update 
0.1 1 - First draft - 
- 2 - None - 
1 3 All 
Additional details added at the request 
of DMC: clarification of primary analysis.  
Formatting updated and some 
additional sections also added to be in 
line with new UKCTU guidance. 
23 Aug 
18 
2 6 
2.3; 3.2; 4; 5; 
6.2 and 8 
Amendments at the request of the DMC 
including addition of detail of per 
protocol, details of complications/SAEs 
and imputation analyses. Small changes 
to layout and removal of typos 
25 Mar 
19 
 
2.3 Supporting documents 
This Statistical Analysis Plan (SAP) should be read in conjunction with the study protocol and WCTU 
Standard Operating Procedures: 
 SOP 8: Statistical Considerations 
 SOP 9: Randomisation and Blinding 
 SOP 15: Information Handling 
 SOP 21: Statistical Analysis Plan 
The Trial Master File, including the Data management Plan can be found in the AIR Trial Manager’s 
office: Warwick Clinical Trials Unit, Clinical Sciences Building, Clinical Sciences Research Laboratories, 
University Hospitals Coventry and Warwickshire, Clifford Bridge Road, Coventry, CV2 2DX 
2.4 Study oversight 
As described in the protocol, the procedures in place for oversight of this study include both a Trial 
Steering Committee (TSC) and Data Monitoring Committee (DMC). The DMC is advisory to the TSC 
and write to the TSC and recommend any alterations to the study to ensure the safety of 
participants and the integrity of the data. 
 
  
  Statistical Analysis Plan 
Final: Version 2, 25 March 19 
Page 5 | 25 
2.5 Roles and responsibilities 
Details of all AIR co-applicants can be found in the protocol. 
Role  Name, address, telephone, email 
Chief Investigator Rebecca Kearney; Associate Professor 
Warwick Clinical Trials Unit, Warwick Medical School,  University of 
Warwick Coventry, CV4 7AL 
Tel: 02476 573156 
Email: r.s.kearney@warwick.ac.uk 
Senior Statistician Helen Parsons; Senior Research Fellow 
Warwick Clinical Trials Unit, Warwick Medical School, University of 
Warwick Coventry, CV4 7AL 
Tel:  02476 572665 
Email: H.Parsons@warwick.ac.uk 
Junior Statistician Philip Wells; Research Assistant 
Warwick Clinical Trials Unit, Warwick Medical School, University of 
Warwick Coventry, CV4 7AL 
Philip.Wells@warwick.ac.uk  
Methodological expert Nick Parsons; Associate Professor 
Warwick Medical School, University of Warwick Coventry, CV4 7AL 
Tel: 02476 150540 
Email: nick.parsons@warwick.ac.uk  
Administrative contact AIR Trial Manager 
Warwick Clinical Trials Unit, Clinical Sciences Building, Clinical 
Sciences Research Laboratories, University Hospitals Coventry and 
Warwickshire, Clifford Bridge Road, Coventry, CV2 2DX  
Tel: 02476 968614  
Email: air@warwick.ac.uk  
Data Monitoring 
Committee 
Chair: Ed Roddy, Reader in Rheumatology 
Research Institute for Primary Care and Health Sciences,  
Keele University, Staffordshire, ST5 5BG 
Tel: 01782 734715  
Email: E.Roddy@keele.ac.uk  
 
Elaine Nicholls, Biostatistician 
Keele Clinical Trials Unit, Keele University, Staffordshire,  
ST5 5BG 
Tel: 01782 734750 
Email: e.nicholls@keele.ac.uk 
 
Michael Whitehouse, Consultant Senior Lecturer 
Musculoskeletal Research Unit, 1st Floor Learning & Research 
Building, School of Clinical Sciences, Southmead Hospital, Bristol, 
BS10 5NB 
Tel: 0117 414 7865 
Email: michael.whitehouse@bristol.ac.uk  
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3 Introduction 
3.1 Background and rationale 
Ankle fractures represent 9% of the trauma workload and demand is increasing. The increasing 
frequency of this injury is a growing burden on the NHS year on year. After ankle fracture, the 
immediate management has traditionally been plaster cast immobilisation for several weeks, whilst 
the bone heals. A cast provides maximum support; however, there are potential problems. Firstly, 
there is the immediate impact on mobility for a period of around six weeks. Secondly, there are the 
risks associated with prolonged immobilisation: muscle atrophy, deep vein thrombosis and joint 
stiffness. Finally, there are the long-term consequences, which include prolonged gait abnormalities, 
persistent calf muscle weakness and an inability to return to previous activity levels. Alternative 
functional bracing may potentially address these issues. However, it does not provide the same 
degree of support to the healing bones. Hence there exists uncertainty about the optimum 
management of ankle fractures. 
The CI has successfully completed a feasibility RCT funded by NIHR RfPB comparing cast with fixed 
angle removable orthotic (FARO) for the management of operative and non-operative ankle 
fractures. The trial ran from August 2015 and completed May 2017, successfully recruiting 50 
participants. This has informed this (main) study, also funded by NIHR.  
More details about the background to the trial can be found in the study protocol. 
3.2 Trial aims and objectives 
This study proposes to answer the question: In adults with an ankle fracture suitable for cast 
immobilisation, does a fixed angle removable orthotic (FARO) improve OMAS 16 weeks post 
randomisation when compared to cast immobilisation? 
3.2.1 Primary objective 
To quantify and draw inferences on observed differences in the OMAS between FARO and cast 
treatment groups at sixteen weeks after randomisation. 
3.2.2 Secondary objectives 
1) To quantify and draw inferences on observed differences in ankle function assessed using 
the OMAS score at 6 weeks, 10 weeks, 24 weeks and 24 months and the MOXFQ 16 weeks 
after randomisation. 
2) To quantify and draw inferences on observed differences in health related quality of life 
(EQ5D-5L) between trial treatment groups At 6 weeks, 10 weeks, 16 weeks, 24 weeks and 24 
months after randomisation. 
3) To quantify and draw inferences on observed differences in disability rating (DRI) between 
trial treatment groups at 6 weeks, 10 weeks, 16 weeks, 24 weeks and 24 months after 
randomisation. 
4)  To quantify and draw inferences on observed differences on complication rates between 
trial treatment groups at 6 weeks, 10 weeks, 16 weeks, 24 weeks and 24 months after 
randomisation. 
5) To estimate comparative cost-utility of the two trial treatment groups and collect resource 
use data at 6 weeks, 10 weeks, 16 weeks, 24 weeks, 12 months, 18 months and 24 months 
after randomisation. 
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4 Study Methods 
4.1 Trial Design 
This study is a UK multi-centre, randomised controlled trial of two parallel treatment arms. 
4.2 Trial interventions 
A full description can be found in the protocol. Briefly; after ankle fracture, patients may require 
ankle fixation surgery prior to being fitted with a cast or brace: 
 All participants who require ankle fixation will have this performed according to the 
preferred technique of the operating surgeon. All participants will then receive normal local 
care until satisfactory clinical wound check, at which point randomization will occur. 
 All participants not receiving surgery will be approached to take part in the trial on first 
presentation to the trauma team fracture clinic, and will be eligible for randomization up to 
a maximum of 3 weeks from injury. 
4.2.1 Control Group - Standard Plaster Cast 
All participants in the control arm will be fitted with cast immobilisation for a minimum of three 
weeks. It is expected that the control intervention will not exceed eight weeks. 
4.2.2 Active Intervention Group – Functional Bracing 
All participants in the intervention arm will be fitted with a FARO for a minimum of three weeks. It is 
expected that the intervention will not exceed eight weeks and the participant will remove the brace 
and perform short exercises. 
4.3 Inclusion and exclusion criteria 
Full descriptions of the inclusion and exclusion criteria can be found in the protocol. A brief summary 
only is provide here. 
4.3.1 Inclusion criteria 
1) Provision of written informed consent. 
2) Aged 18 years or over. 
3) A closed ankle fracture where a plaster cast is a management option. 
4) Within 3 weeks of operative management or injury if non-operative. 
4.3.2 Exclusion criteria 
1) Ankle fracture secondary to known metastatic disease. 
2) Complex intra-articular fracture. 
3) The patient would require manipulation and close contact casting. 
4) In the opinion of the surgeon the patient would require manipulation and moulded cast. 
5) Wound complications following surgical management contraindicating FARO intervention. 
6) Previous ankle fracture randomised in the present trial. 
7) The patient is unable to adhere to trial procedures or complete postal questionnaires. 
8) Known pre-existing neuropathic joint disease contraindicating FARO intervention 
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4.4 Trial flow chart 
Figure 1: CONSORT chart 
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4.5 Schedule of assessments 
Table 1: Trial assessments 
Visit no. 1 2 3 4 5 6 7 8 9 
Visit Window  
(Scheduled time ± allowance)  
Pre -
Consent 
Baseline 
(0) 
6wk 
(± 2wk) 
after V2 
10wk 
(± 2wk) 
after V2 
16 wk 
(± 4 wk) 
after V2 
24 wk 
(± 4 wk) 
after V2 
12 m 
(± 1m) 
after V2 
18 m 
(± 1m) 
after V2 
24 m 
(± 1m) 
after V2 
Eligibility Check          
Written and verbal information provided          
Written informed consent          
Baseline CRFs (Pre and Post injury)          
Randomisation          
Intervention delivery          
OMAS (Critical data item)          
MOXFQ          
DRI          
EQ5D5L (Critical data item)          
Resource use questionnaires          
Complications (Critical data item)          
Global Impression of Change  
(Critical data item) 
        
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4.6 Randomisation and blinding 
Pre-randomisation eligibility checks will be carried out to ensure that potential participants meet the 
eligibility criteria and are not randomised in error. Written informed consent for entry into the trial 
and baseline assessment must be obtained prior to randomisation. Subjects will be randomised 
strictly sequentially, as they become registered as eligible for randomisation on the web based 
system. Allocation concealment will be maintained by an independent randomisation team who will 
be responsible for generation of the sequence and will have no role in the allocation of participants. 
The treatment group will be allocated by computer using a minimisation algorithm with a random 
element and stratification by centre, age (<50 vs ≥50) and operative/non operative management 
following use of a secure web based randomisation service. 
No blinding of participants or clinical staff is possible due to the nature of the intervention arms. 
Furthermore, outcome data to be entered onto the trial database will contain treatment identifying 
variables, making blinding of the trial team impracticable; however, blinding of the trial team will be 
maintained where possible. 
 
4.7 Sample size 
The primary outcome for this study is the OMAS 16 weeks post injury. The minimum clinically 
important difference (MCID), or smallest between group difference that is likely to be clinically 
meaningful beyond measurement error for foot and ankle conditions is a change of 10 points. This is 
consistent with the AIM study [1], which set the OMAS equivalence margin between groups to be 6 
points. It is also consistent with other similar outcome measures such as the Foot and Ankle 
Outcome Score [2], and visual analogue pain scores in acute injury; that report MCIDs of 
approximately 10 points on a 100 point scale. 
The standard deviation (SD) of the OMAS at six months after injury from previous feasibility work 
was approximately 28 points. To account for any variation arising from recruiting from multiple 
study centres and to allow that the primary outcome has been moved from this time point, we have 
selected a conservative estimation of the trial SD of 30 points. This corresponds to a moderate 
standardised effect size of 0.33. Hence, the total trial sample size required to detect a difference of 
10 points given a SD of 30 points with two-sided significance set at 5% and 90% power is 382 
participants. 
Allowing a margin of 20% loss during follow-up (whilst striving to keep this below 10%), this gives a 
figure of 478 participants in total. Therefore, a minimum of 239 participants randomised to each 
group will provide 90% power to detect a difference of 10 points in OMAS at sixteen weeks at the 5% 
level. 
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5 Outcomes 
5.1 Primary outcome measure 
The primary outcome for the AIR study is the Olerud and Molander Ankle Score (OMAS). The OMAS 
a self-administered questionnaire which is suitable for assessing symptoms after an ankle fracture. 
The OMAS is measured on a scale between 0 and 100, where higher scores denote better function. 
The score will be calculated as standard [3] and is based on nine different items: pain, stiffness, 
swelling, stair climbing, running, jumping, squatting, supports and work/activities of daily living.  
For responses which contain missing items, the OMAS will be calculated by assuming that the 
missing item scores were zero for those responses where the sum of the maximum missing scores 
does not exceed 25 (inclusive) points. Instances where the maximum missing score is greater than 
25 will be assumed to be missing and treated as described in section 6.3. 
5.2 Secondary outcome measures 
The following secondary outcome measures will also be collected: 
EQ-5D: Is a validated, generic health-related quality of life measure consisting of five items each with 
a 5 possible responses. These are then converted into a health utility score. EQ-5D-5L responses will 
be used to generate health preference values using the UK time-trade-off (TTO) value set 
recommended [4], or those recommended for use by the Health Economic Team. 
MOXFQ: The Manchester-Oxford Foot Questionnaire (MOXFQ) [5] is a validated questionnaire which 
is self-reported. It contains 16 items, each with 5 response options comprising 3 separate underlying 
dimensions: Walking/standing problems (7 items), foot pain (5 items) and issues related to social 
interaction (4 items). Item responses are each scored from 0 to 4, with 4 representing the most 
severe state. The scale scores representing each dimension are produced by summing the responses 
to each item within that dimension. Raw scale scores are then converted to a metric (0-100; 
100=most severe). 
DRI: The Disability Rating Index (DRI) is a self-administered questionnaire. It consists of 12 items 
specifically related to function of the lower limb. Each item is a visual analogue scale with anchor 
points of 0 and 100 and the summary score is simply the mean of all items [6].  
Complications: All complications will be recorded, including mal-union, delayed/non-union, 
infection, wound complications after surgery, vascular injury, neurological injury, and venous 
thromboembolism. A record will also be kept of any other surgery required in relation to the index 
fracture.  
Radiology: All baseline X-Ray/radiographs and also the last X-Ray/radiograph taken before the 
primary outcome point of 16 weeks will be collected. As very little evidence of an association 
between ankle function and radiology outcomes were found from the feasibility study [7] (paper in 
preparation), it was decided that while the radiology outcomes would be collected, they would not 
constitute part of the main trial analysis. It will, however, be possible to carry out exploratory 
analysis using relevant radiology outcomes, if deemed appropriate, at a later date. 
Resource use: details of resource use have been collected to inform the economic analysis. Hence, 
further details can be found in the protocol and Health Economics Analysis Plan (HEAP). 
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5.3 Adherence and compliance 
Compliance with the intervention is captured on patient completed CRFs. This consists of asking the 
participant to report at 6, 10 and 16 weeks if:  
 They are still wearing cast or FARO given at randomisation 
 If they have had a replacement cast or FARO, and if so when was and what was the 
replacement 
The time the participant wore the cast or FARO will be calculated and the participant will be 
considered to have not adhered if this time is 21 days or fewer. If the participant reports multiple 
dates which they discontinued the intervention, the smallest time to discontinuation will be used. 
The effect of compliance on the primary outcome will be assessed by carrying out per-protocol 
analysis as a secondary analysis and comparing the results of this to the primary analysis (intention 
to treat).  The per-protocol approach will follow the methods set out for the primary analysis (see 
section 6.1), but only include those participants who have worn their treatment (cast or FARO) for at 
least three weeks. Participants who change their intervention after three weeks (>21 days) will 
therefore still be classified as wearing their intervention for this analysis.  
Further protocol deviations and violations observed in the study can be dealt with as appropriate, 
dependent on the observed data. For example, if a large number of participants are observed to 
wear a single intervention for less than three weeks, a “dose delivered” analysis will be considered. 
 
5.4 Minimal data set 
The following outcomes are considered the core outcome set to be collected if the entirety of the 
CRF cannot be collected. For example; by telephone follow up after non-return of postal 
questionnaire 
1. OMAS (all time points) 
2. Complications (all time points) 
3. EQ5D (all time points) 
4. Global impression of change (16 week time point only) 
6 Analysis strategy 
The routine statistical analysis will mainly be carried out using R [8] or Stata (StataCorp. 2017. Stata 
Statistical Software: College Station, TX: StataCorp LP). 
All data will be analysed and reported in accordance with the CONSORT statement. [9] Treatment 
effects will be presented, with appropriate 95% confidence intervals, for both the unadjusted and 
adjusted analyses. Tests will be two-sided and considered to provide evidence for a significant 
difference if p-values are less than 0.05 (5% significance level). All analyses will be conducted as 
intention to treat unless otherwise specified. 
Standard descriptive summaries will be provided for the primary outcome measure (OMAS) and all 
secondary outcome measures. Baseline data will be summarised to check comparability between 
treatment arms, and screening data will be checked to highlight any characteristic differences 
between those individuals in the study, those ineligible, and those eligible but withholding consent. 
Patient reported outcome measure (PROM) data, such as the OMAS scores, will be assumed to be 
  Statistical Analysis Plan 
Final: Version 2, 25 March 19 
Page 13 | 25 
normally distributed during modelling, but subsidiary analyses may also be undertaken after 
appropriate variance-stabilising transformation if assumptions of normality prove to be 
unsustainable. 
 
6.1 Primary analysis 
The main analysis will investigate differences in the primary outcome measure, sixteen weeks after 
randomisation, between the two treatment groups. The differences between treatment groups will 
initially be assessed using a t-test, based on a normal approximation for the OMAS score at 16 
weeks. In addition, regression analyses to adjust for any imbalance between test treatment groups 
as well as pre-injury function, patient age, gender and operative treatment (Yes or No) will also be 
carried out.  
This fixed effects model will also be generalised by adding a random effect for recruiting centre to 
allow for possible heterogeneity in patient outcomes due more generally to the recruiting centre. 
Since individual clinicians will treat only a small number patients enrolled in the trial, we do not 
expect clinician specific effects to be important in this study and hence these will not be modelled. 
This adjusted mixed-effects linear regression analysis will be reported as the primary analysis, and 
will be used to assess evidence for differences in outcomes between intervention arms. 
 
6.2 Secondary analyses 
The primary analysis will also be conducted on a per protocol basis based on patient reported 
adherence to their intervention group and will also be conducted as a sensitivity analysis. Further 
details on how per-protocol is being defined for the purposes of this trial have been given in section 
5.3. 
Descriptive statistics of PROM data (OMAS, MOSFQ, EQ5D and DRI) at each time point collected (6 
weeks, 10 weeks, 16 weeks, 24 weeks 12 months, 18 months and 24 months after randomisation) 
will be constructed with between group analyses following the method set out for the primary 
analysis above.  
Complications will be summarised with between groups comparisons evaluated using chi-squared 
tests. Temporal patterns of any complications will be presented graphically and if appropriate, a 
time-to-event analysis (e.g. Kaplan-Meier survival analysis) will be used to assess the overall risk and 
risk within individual classes of important complications (e.g. non-union). 
Other outcomes (e.g. Physiotherapy outcomes, weight bearing status) will be summarised and 
compared between groups using appropriate tests for the outcome (e.g. proportions and chi-
squared tests for binary outcomes, means and t-tests for continuous data). 
 
6.3 Missing data 
It seems likely that some data may not be available due to voluntary withdrawal of patients, lack of 
completion of individual data items or general loss to follow-up. Where possible the reasons for data 
‘missingness’ will be ascertained and reported. The nature and pattern of the missingness will be 
carefully considered, including whether data can be treated as missing completely at random 
(MCAR). Little’s test will be used to assess whether the data can be considered MCAR or missing at 
random (MAR) and/or missing not at random (MNAR). An assessment between MAR and MNAR is 
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subjective, so cannot be tested [10]. Variables that will be checked for their impact on missingness 
rates will include: the intervention received, site of randomisation, age (<50 vs ≥50) and whether the 
participant received operative or non-operative management   
If judged appropriate, missing data will be imputed using multiple imputation. Any imputed analyses 
will be considered as secondary analyses and will be reported along with the primary analysis. 
If imputation is undertaken, the resulting imputed datasets will be analysed, together with 
appropriate sensitivity analyses. Any imputation methods used for scores and other derived 
variables will be carefully considered and justified. In particular the model used for the multiple 
imputation will be assessed along with the plausibility of any imputed values. Reasons for 
ineligibility, non-compliance, withdrawal or other protocol violations will be stated and any patterns 
summarised. More formal analysis, for example using logistic regression with ‘protocol violation’ as a 
response, may also be appropriate and aid interpretation. 
 
6.4 Subgroup analyses  
Two pre-specified sub-group analyses will be undertaken to assess whether there is evidence that 
the intervention effect differs between whether:  
i. The study participants receives operative or non-operative treatment prior to the study 
intervention  
ii. The study participants are aged 50 or over at study randomisation  
The subgroup analyses will follow the methods described for the primary analysis, with additional 
interaction terms incorporated into the mixed-effects regression model to assess the level of 
support for these hypotheses. The study is not powered to formally test these hypotheses, so they 
will be reported as exploratory analyses only, and as subsidiary to the analysis reporting the main 
effects of the intervention in the full study population at the 16 week primary endpoint.  
7 Interim analyses 
No interim analyses are planned, and will be carried out only at the direction of the DMC. 
 
8 Safety and adverse event reporting 
Safety monitoring will be conducted primarily through the participant self-reporting. At each follow 
up point, participants will be asked if they have had any adverse events and how these were 
managed using a postal questionnaire.  
Complications deemed serious will be reported separately as SAEs. The number and nature will be 
reported and assessed by intervention arm, as shown in Table 12 of the dummy tables. 
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10 Dummy tables 
The following tables fill form the basis for the final statistical report. For brevity, some tables which 
have are reported at multiple time points are shown once; with variables noted when reported 
where necessary. Note also that variable level missingness is not reported here, but will be marked 
in the final report as appropriate. 
 
Table 2: Participant flow from screening data 
Reason not recruited n 
In
el
ig
ib
le
 
Known metastatic disease  
Complex, intra-articular fracture  
Requires manipulation and close contact casting  
Requires manipulation and moulded cast  
Wound complication contraindicates FARO  
Previous entry in trial  
Patient unable to adhere to trial procedures  
Neuropathic joint disease contraindicates FARO  
El
ig
ib
le
, 
p
at
ie
n
t 
u
n
w
ill
in
g Prefer plaster cast  
Prefer functional brace  
Does not want to take part in research  
Other  
O
th
e
r Patient missed  
Clinician unwilling  
Other  
 
Table 3: Summary of screened participant characteristics. Values reported are means and standard deviations unless 
otherwise stated 
 Randomised (n=) Eligible, not randomised (n= ) 
Gender: Male (n, %)   
Age (years)   
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Table 4: Recruitment by site 
Code Site name 
Plaster cast 
(n) 
Functional 
brace (n) 
Total 
(n) 
UHC University Hospitals Coventry and Warwickshire    
NBT North Bristol Southmead    
RLH Royal London Hospital    
NTH North Tees and Hartlepool    
NGH Sheffield Northern General Hospital    
KCH Kings College Hospital    
RVI Royal Victoria Newcastle upon Tyne    
MKH Milton Keynes University Hospital    
TNH Tayside Ninewells Hospital Dundee    
SHK St Helens and Knowsley    
LDH Luton and Dunstable    
RNT Rotherham NHS Trust    
UHL United Lincolnshire Hospital    
ELH East Lancashire    
RBH Royal Berkshire Hospital    
LHS Lister Hospital Stevenage    
UHS Uni Hospitals Southampton    
STH South Tees Hospital    
BHN Bedford Hospitals NHS Trust    
LRI Leicester Royal Infirmary     
Total    
 
Table 5: Withdrawal and loss to follow up 
Trial status Time point 
Plaster cast 
(n) 
Functional 
brace (n) 
Total 
(n) 
Withdrawn from 
study (n, %) 
Baseline    
6 weeks    
10 weeks    
16 weeks    
24 weeks    
12 months    
18 months    
24 months    
Questionnaire 
not returned  
(n, %) 
Baseline    
6 weeks    
10 weeks    
16 weeks    
24 weeks    
12 months    
18 months    
24 months    
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Table 6: Baseline data. Values reported are means and standard deviations unless otherwise stated 
 Plaster cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
Age (years)    
Age group: 49 years or under (n, %)    
Gender: Male (n, %)    
BMI (kg/m2)    
Diabetic: Yes (n, %)    
Leg fracture in last 12 months (n, %)    
Tendon/nerve injury in last 12 months (n, %)    
Currently taking steroids (n, %)    
Other medications: Yes (n, %)    
Smokes: Yes (n, %)    
Alcohol per 
week 
(n, %) 
0 – 7 units    
8 – 14 units    
15 – 21 units    
More than 21 units    
Ethnicity (n, %) 
White    
Asian/Asian British    
Mixed/multiple ethnic groups    
Black/ African/ Caribbean/ 
Black British 
   
Other ethnic group    
Employment 
status (n, %) 
Full-time employed    
Part time employed    
Self-employed    
Retired/looking after home    
Unpaid work    
Unemployed    
Full time student    
Employment 
category (n, %) 
Unskilled manual    
Skilled manual    
Unskilled non-manual    
Skilled non-manual    
Professional    
Other    
Interventional 
preference 
(n, %) 
Plaster cast    
Functional brace    
No preference    
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Table 7: Injury data. Values reported are numbers and percentages unless otherwise stated 
 
Plaster cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
Injury CRF completed    
Side of fracture: Left     
Mechanism of 
injury* (n, %) 
Low energy fall    
High energy fall    
Road traffic accident    
Crush injury    
Contact sports injury    
Other    
Lateral malleolus affected: Yes    
Lateral malleolus affected: Weber A    
Lateral malleolus affected: Weber B    
Lateral malleolus affected: Weber C    
Medial malleolus affected: Yes    
Posterior malleolus affected: Yes    
Ankle fracture treatment: Operative    
Advised weight 
bearing status 
Fully    
Partial    
None    
Concurrent 
injuries* (Yes) 
Head    
Chest    
Abdomen    
Pelvis    
Spine    
Shoulders/arms    
Opposite leg    
Same leg    
*Participant can be included in multiple categories 
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Table 8: Operation data. Values reported are numbers and percentages unless otherwise stated 
 
Plaster cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
CRF returned    
Length of operation, mins (mean, SD)    
Lead surgeon 
grade 
Consultant    
Specialist Trainee    
Staff grade/associate specialist    
Other    
Number of years at this grade (mean, SD)    
Other surgeons present: Consultant  
(mean, SD) 
   
Other surgeons present: Specialist Trainee 
(mean, SD) 
   
Other surgeons present: Staff grade/ associate 
specialist (mean, SD) 
   
Intra-operative complications: Yes    
Intra-operative complications: Nerve Injury    
Intra-operative complications: Vascular Injury    
Intra-operative complications: Tendon Injury    
Intra-operative complications: Other    
Lateral malleolus fixed: Yes    
Lateral malleolus fixed: No. of fibula screws 
(mean, SD) 
   
Lateral malleolus fixed: 
plate used 
Locking    
Non locking    
No plate    
No. of syndesmosis screws used (mean, SD)    
Syndesmosis tightrope used: Yes    
Medial malleolus fixed: Yes    
Medial malleolus fixed: No. of screws  
(mean, SD) 
   
Medial malleolus fixed: Plate used    
Medial malleolus fixed: Tension band used    
Posterior malleolus fixed: Yes    
Posterior malleolus fixed: No. of screws  
(mean, SD) 
   
Posterior malleolus fixed: Plate used    
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Table 9: Patient reported outcome measures. Values reported are means and standard deviations unless otherwise stated 
PROM Time point 
Plaster cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
OMAS 
Pre injury    
Post injury    
6 weeks    
10 weeks    
16 weeks    
24 weeks    
24 months    
MOXFQ 
Pre injury    
Post injury    
16 weeks    
24 months    
DRI 
Pre injury    
Post injury    
6 weeks    
10 weeks    
16 weeks    
24 weeks    
24 months    
EQ5D 
Pre injury    
Post injury    
6 weeks    
10 weeks    
16 weeks    
24 weeks    
12 months    
18 months    
24 months    
Global impression of change  
(16 weeks only) 
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Table 10: Patient reported wound complications post-surgery at specified time points for participants who had surgical 
fracture management. Values reported are numbers and percentages unless otherwise stated 
Time point Wound complication 
Plaster 
cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
No. 
deemed 
serious 
6 weeks; 
10 weeks; 
16 weeks; 
24 weeks; 
24 months 
Issues with wound healing: 
Yes 
   
 
Discharge from wound: Any     
Discharge from wound: Clear 
or blood stained 
   
 
Discharge from wound: 
Yellow/green pus 
   
 
Increased pain: Yes     
Become swollen     
Edges of wound separated     
Lab sample taken     
 
Table 11: Patient reported complications at specified time points. Values reported are numbers and percentages unless 
otherwise stated 
Time point Complication 
Plaster 
cast (n=) 
Functional 
brace (n=) 
Total 
(n=) 
No. 
deemed 
serious 
6 weeks; 
10 weeks; 
16 weeks; 
24 weeks; 
24 months 
Pressure sore/ulcer     
Numbness at side of foot     
Problems with fracture healing     
 
Table 12: Expected Serious Adverse Events (SAEs) 
SAE 
Plaster cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
All expected SAEs    
Participant experienced any expected SAE     
Further surgery for ankle fracture    
Ankle surgery: Removal of metalwork    
Ankle surgery: Fixed with metalwork    
Ankle surgery: Metalwork replaced    
Ankle surgery: Wound washout    
Ankle surgery: Other    
Ankle surgery: Not sure why    
Deep Vein Thrombosis (DVT)    
DVT: confirmed with ultrasound    
DVT: prescribed medicine    
Pulmonary Embolism (PE)    
PE: confirmed by CT Pulmonary Angiogram    
PE: prescribed medicine    
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Table 13: Unexpected, unrelated Serious Adverse Events (SAEs) 
SAE 
Plaster cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
All SAEs (n)    
Participant experienced any SAE (n, %)    
SAE: death (n, %)    
SAE: life threatening (n, %)    
SAE: requires/extends hospitalisation (n, %)    
SAE: persistent or significant disability or 
incapacity (n, %) 
   
SAE: Requires medical intervention to prevent 
one of the above, or otherwise significant (n, %) 
   
 
Table 14: Unexpected, related Serious Adverse Events (SAEs) 
SAE 
Plaster cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
All SAEs (n)    
Participant experienced any SAE (n, %)    
SAE: death (n, %)    
SAE: life threatening (n, %)    
SAE: requires/extends hospitalisation (n, %)    
SAE: persistent or significant disability or 
incapacity (n, %) 
   
SAE: Requires medical intervention to prevent 
one of the above, or otherwise significant (n, %) 
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Table 15: Fracture management at specified time points. Values reported are numbers and percentages unless otherwise 
stated 
Time point Wound complication 
Plaster cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
6 weeks 
only 
Patient reported allocation: 
Functional Brace 
   
Received 
allocated 
treatment 
Yes    
No, patient choice    
No, clinician choice    
No, other    
Received VTE prophylaxis: Yes    
Received VTE prophylaxis: No. of 
weeks (mean, SD) 
   
6 weeks;  
10 weeks 
Patient reported 
weight bearing 
status 
Full weight    
Some weight    
No weight    
Weight bearing same as 
instructed: Yes 
   
6 weeks; 
10 weeks; 
16 weeks 
Still wearing brace/cast    
Changed intervention: Yes    
Intervention 
change to: 
Plaster cast    
Functional brace    
 
 
Table 16: Physiotherapy at specified time points. Values reported are numbers and percentages unless otherwise stated 
Time point Physiotherapy outcome 
Plaster cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
6 weeks; 
10 weeks; 
16 weeks; 
24 weeks 
Referred to physiotherapy: Yes    
Referred to 
foot and ankle 
class 
Yes    
No    
Unknown    
Referred to 
individual 
physiotherapy 
Yes    
No    
Unknown    
6 weeks; 
10 weeks; 
16 weeks; 
24 weeks; 
24 months 
Received physiotherapy: Yes    
If received physio: No. of 
appointments (mean, SD) 
   
6 weeks;  
10 weeks 
If received brace: completing 
daily exercises 
   
10 weeks 
16 weeks 
24 weeks 
24 months 
Received physio: discharged    
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Table 17: Fidelity and adherence outcomes 
 
Plaster cast 
(n=) 
Functional 
brace (n=) 
Total 
(n=) 
Intervention not worn for 3 weeks (n, %)    
Protocol deviations (n)    
 
 
